亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

医学 吉西他滨 耐受性 无容量 内科学 肿瘤科 胃肠病学 人口 胆囊癌 癌症 不利影响 免疫疗法 环境卫生
作者
Makoto Ueno,Masafumi Ikeda,Chigusa Morizane,Satoshi Kobayashi,Izumi Ohno,Shunsuke Kondo,Naohiro Okano,Keisuke Kimura,Suguru Asada,Yoshinobu Namba,Takuji Okusaka,Junji Furuse
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:4 (8): 611-621 被引量:331
标识
DOI:10.1016/s2468-1253(19)30086-x
摘要

Background This study aimed to assess the safety and tolerability of the immune checkpoint inhibitor nivolumab, as monotherapy or combined with chemotherapy, in Japanese patients with biliary tract cancer. Methods This multicentre, open-label, phase 1 trial was done at four cancer centres in Japan. Eligible patients were aged 20–79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis. Patients with unresectable or recurrent biliary tract cancer that was refractory or intolerant to gemcitabine-based treatment regimens received nivolumab monotherapy (240 mg every 2 weeks [monotherapy cohort]). Chemotherapy-naive patients with unresectable or recurrent biliary tract cancer received nivolumab (240 mg every 2 weeks) and cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) chemotherapy (combined therapy cohort). The primary objective was to assess tolerability and safety. The primary objective was assessed in the safety population of all patients who had received at least one dose of nivolumab. This study is registered with www.clinicaltrials.jp, number JapicCTI-153098, and follow-up is ongoing. Findings 30 patients were enrolled into each cohort between Jan 13, 2016, and April 19, 2017. Data cutoff was Aug 31, 2017. In the monotherapy cohort, the most frequently reported treatment-related adverse events were decreased appetite (five [17%]), malaise (four [13%]), and pruritus (four [13%]). Grade 3–4 treatment-related adverse events were reported by three (10%) patients (rash, maculopapular rash, and amylase increase) and treatment-related serious adverse events were reported by one (3%) patient (pleurisy). In the combined therapy cohort, the most frequently reported treatment-related adverse events were neutrophil count decrease (any grade 25 [83%]; grade 3–4 in 23 [77%] patients) and platelet count decrease (any grade 25 [83%] of 30; grade 3–4 in 15 [50%] patients). Six (20%) patients reported 11 treatment-related serious adverse events (platelet count decrease [three patients], febrile neutropenia [two patients], neutrophil count decrease, anaemia, anaphylactic reaction, decreased appetite, pyrexia, and myocarditis [one patient each]). In the monotherapy cohort, median overall survival was 5·2 months (90% CI 4·5–8·7), median progression-free survival was 1·4 months (90% CI 1·4–1·4), and one of 30 patients had an objective response. In the combined therapy cohort, median overall survival was 15·4 months (90% CI 11·8–not estimable), median progression-free survival was 4·2 months (90% CI 2·8–5·6), and 11 of 30 patients had an objective response. Interpretation Nivolumab had a manageable safety profile and signs of clinical activity in patients with unresectable or recurrent biliary tract cancer. This initial assessment of nivolumab for the treatment of advanced biliary tract cancer provides supportive evidence for future larger randomised studies of nivolumab in this difficult to treat cancer. Funding Ono Pharmaceutical Co Ltd and Bristol-Myers Squibb Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
anniver732发布了新的文献求助10
刚刚
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助10
1秒前
anniver732发布了新的文献求助20
1秒前
anniver732发布了新的文献求助10
1秒前
1秒前
所谓完成签到,获得积分20
2秒前
2秒前
2秒前
anniver732发布了新的文献求助10
4秒前
anniver732发布了新的文献求助10
4秒前
anniver732发布了新的文献求助10
4秒前
十四发布了新的文献求助10
5秒前
迷人宛亦发布了新的文献求助10
6秒前
7秒前
sailor发布了新的文献求助10
8秒前
molihuakai的应助被科研通管家采纳,获得10
9秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
9秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
9秒前
null的应助被科研通管家采纳,获得10
9秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
9秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
9秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
10秒前
天天快乐的应助被科研通管家采纳,获得10
10秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
10秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
10秒前
18秒前
sailor完成签到,获得积分10
21秒前
可爱的函函的应助被DRJ采纳,获得10
25秒前
踏实的又夏完成签到 ,获得积分10
25秒前
共享精神的应助被sailor采纳,获得10
27秒前
38秒前
44秒前
涛1118发布了新的文献求助10
45秒前
笑哈哈完成签到,获得积分10
45秒前
单纯的天抒完成签到,获得积分10
48秒前
49秒前
dalang完成签到 ,获得积分10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667